ALKS Stock Rises 27% in 3 Months: Here's What You Should Know

The company recently reported second-quarter 2026 results, wherein sales of its proprietary products portfolio grew 34% year over year to $411.7 million. Importantly, sales exceeded management’s guided range of $385-$405 million for the quarter.

Strong demand for its proprietary products is supporting Alkermes’ top-line growth and driving the stock, with the company expecting continued momentum through the remainder of 2026.

Year to date, shares of Alkermes have rallied 75.9% compared with the industry’s rise of 6.4%.

Image Source: Zacks Investment Research

ALKS’ Strong Product Portfolio Aids Growth

In the first six months of 2026, Vivitrol and Aristada generated sales of $236.9 million and $190.5 million, respectively, up 6.4% and 9% year over year. Sales of both drugs benefited from underlying demand.

Notably, growth in the alcohol-dependence treatment market has helped drive new patients toward Vivitrol, while Aristada continues to generate steady sales.

In the first six months of 2026, Lybalvi generated sales of $186.3 million, up 20.7% year over year, driven by an increase in total prescriptions.

Alkermes added the narcolepsy drug Lumryz to its portfolio following the acquisition of Avadel Pharmaceuticals in February 2026. Lumryz generated $136.1 million in revenues during the first six months of 2026 following its addition to Alkermes’ portfolio.

Reflecting the growing momentum across its product portfolio, Alkermes expects Vivitrol sales to be in the range of $460-$480 million, while Aristada sales are anticipated in the range of $365-$385 million in 2026.

Lybalvi sales are expected to be in the range of $380-$400 million, while Lumryz sales are expected to be in the range of $315-$335 million in 2026.

ALKS' Ongoing Pipeline Development Activities

Alkermes is developing alixorexton, a novel, investigational, oral, selective orexin 2 receptor agonist for treating narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) in late-stage studies, as well as idiopathic hypersomnia (IH) in a mid-stage study.

In June 2026, the FDA granted orphan drug designation (ODD) to alixorexton for the treatment of IH. The European Commission also granted ODD to alixorexton for the treatment of patients with narcolepsy.

With certain clinical milestones expected later this year, successful development and potential approval of alixorexton could provide Alkermes with an additional long-term growth opportunity.

The consistent growth of its proprietary product portfolio, coupled with continued clinical progress with alixorexton, provides Alkermes with multiple growth drivers. These catalysts could support the company’s long-term growth prospects and help maintain positive momentum in the stock.

ALKS' Zacks Rank & Stocks to Consider

Alkermes currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have gained 0.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 154.1% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research